2. Search Result
Search Result
Results for "

CRF1

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

11

Peptides

1

Recombinant Proteins

1

Isotope-Labeled Compounds

3

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106203
    Crinecerfont

    SSR-125543

    		 CFTR Metabolic Disease
    Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency [1] . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont
  • HY-12129
    CP 154526 hydrochloride

    		CFTR Neurological Disease
    CP 154526 hydrochloride is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki of 2.7 nM. CP 154526 hydrochloride shows selective for CRF1 over CRF2 (Ki = >10 μM). CP 154526 hydrochloride has anxiolytic activities [1] .
    CP 154526 hydrochloride
  • HY-12127
    Pexacerfont

    BMS-562086

    		 CRFR Neurological Disease Endocrinology
    Pexacerfont is a selective corticotropin-releasing factor (CRF1) receptor antagonist with IC50 of 6.1±0.6 nM for human CRF1 receptor.
    Pexacerfont
  • HY-14875
    Verucerfont

    GSK561679

    		 CRFR Neurological Disease Endocrinology
    Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000?nM for CRF1, CRF2, and CRF-BP, respectively.
    Verucerfont
  • HY-14130
    CP 376395

    		CRFR Neurological Disease Endocrinology
    CP 376395 is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist [1] .
    CP 376395
  • HY-106203A
    Crinecerfont hydrochloride

    SSR-125543 hydrochloride

    		 CFTR Metabolic Disease
    Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency [1] . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont hydrochloride
  • HY-14127
    R121919
    Maximum Cited Publications
    7 Publications Verification

    NBI30775

    		 CRFR Neurological Disease Endocrinology
    R121919 (NBI30775) is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 has antidepressant and anxiolytic effects. R121919 alleviates defensive withdrawal in rats [1] .
    R121919
  • HY-P1294
    α-Helical CRF(9-41)

    		CRFR Neurological Disease
    α-Helical CRF(9-41) is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) is also a partial agonist of CRF1 receptor with an EC50 of 140 nM [1] .
    α-Helical CRF(9-41)
  • HY-P2287
    Cortagine
    3 Publications Verification

    		 CRFR Neurological Disease
    Cortagine is a specific corticotropin-releasing factor receptor subtype 1 (CRF1) agonist with an EC50 of 2.6 nM for rCRF1. Cortagine is an anxiolytic and antidepressive agent in the mouse model [1].
    Cortagine
  • HY-P1108
    Astressin 2B
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 [1] .
    Astressin 2B
  • HY-113603
    Tildacerfont

    SPR001; LY2371712

    		 CRFR Metabolic Disease
    Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia [1].
    Tildacerfont
  • HY-P1107
    Antisauvagine-30
    4 Publications Verification

    aSvg-30

    		 CRFR Neurological Disease
    Antisauvagine-30 (aSvg-30) is a potent, competitive and selective CRF2 receptor antagonist with Kd values of 1.4 nM and 153.6 nM for mouse CRF2β and rat CRF1 receptors, respectively [1].
    Antisauvagine-30
  • HY-P1294A
    α-Helical CRF(9-41) TFA

    		CRFR Neurological Disease
    α-Helical CRF(9-41) TFA is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) TFA is also a partial agonist of CRF1 receptor with an EC50 of 140 nM [1] .
    α-Helical CRF(9-41) TFA
  • HY-P1296
    Urocortin, rat

    Urocortin (Rattus norvegicus); Rat urocortin

    		 CRFR Neurological Disease Endocrinology
    Urocortin, rat (Urocortin (Rattus norvegicus)) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively [1] .
    Urocortin, rat
  • HY-14367
    Emicerfont

    GW876008

    		 CRFR Neurological Disease Endocrinology
    Emicerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist with an IC50 of 66 nM.
    Emicerfont
  • HY-156522
    CRF1 receptor antagonist-1

    		CFTR Endocrinology
    CRF1 receptor antagonist-1 (Compound 2) is a CRF1 receptor antagonist. CRF1 receptor antagonist-1 can be used for research of congenital adrenal hyperplasia (CAH) [1].
    CRF1 receptor antagonist-1
  • HY-P1368
    Stressin I
    1 Publications Verification

    Cyclo(31-34)[DPhe12,Nle21,38,Glu31,Lys34]Ac-hCRF(4-41)

    		 CRFR Endocrinology
    Stressin I (Cyclo(31-34)[DPhe12,Nle21,38,Glu31,Lys34]Ac-hCRF(4-41)) is a potent CRF1 receptor-selective agonist with a Ki of 1.7 nM. Stressin I induces increases in adrenocorticotropic hormone (ACTH) levels in rats [1].
    Stressin I
  • HY-113603S
    Tildacerfont-d8

    SPR001-d8; LY2371712-d8

    		 Isotope-Labeled Compounds CRFR Cancer
    Tildacerfont-d8 (SPR001-d8; LY2371712-d8) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia [1].
    Tildacerfont-d8
  • HY-P1368A
    Stressin I TFA
    1 Publications Verification

    Cyclo(31-34)[DPhe12,Nle21,38,Glu31,Lys34]Ac-hCRF(4-41) TFA

    		 CRFR Endocrinology
    Stressin I (Cyclo(31-34)[DPhe12,Nle21,38,Glu31,Lys34]Ac-hCRF(4-41)) TFA is a potent CRF1 receptor selective agonist, Ki is 1.7 nM. Stressin I induces an increase in adrenocorticotropic hormone (ACTH) levels in rats [1] [1].
    Stressin I TFA
  • HY-12130
    CP 154526

    		CRFR Neurological Disease
    CP 154526 is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki of 2.7 nM. CP 154526 shows selective for CRF1 over CRF2 (Ki = >10 μM). CP 154526 has anxiolytic activities [1] .
    CP 154526
  • HY-182645
    CRF1 receptor antagonist-2

    		CRFR Neurological Disease
    CRF1 receptor antagonist-2 is an orally active, blood-brain barrier permeable CRF1 receptor antagonist, with an IC50 of 4 nM in CHO-K1 cell membranes and an IC50 of 7 nM in rat brain cell membranes. CRF1 receptor antagonist-2 exerts anxiolytic effects in swim stress-loaded rats. CRF1 receptor antagonist-2 can be used in studies related to stress-induced anxiety [1].
    CRF1 receptor antagonist-2
  • HY-103378
    NBI 35965 methanesulfonate

    		CRFR Neurological Disease
    NBI 35965 methanesulfonate is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 methanesulfonate does not inhibit CRF2. NBI 35965 methanesulfonate reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI 35965 methanesulfonate shows anxiolytic effects [1] .
    NBI 35965 methanesulfonate
  • HY-14128
    NBI-34041

    SB-723620

    		 CRFR Neurological Disease
    NBI-34041 (SB-723620) is a selective and orally active nonpeptide CRF1 receptor antagonist with an IC50 of 58.9 nM and a Ki of 4.0 nM for human CRF1 receptor. NBI-34041 has no inhibitory effect on the CRF2 receptor. NBI-34041 can be used for depression and anxiety disorders research.
    NBI-34041
  • HY-119114
    E-2508 free base

    		CRFR Neurological Disease
    E-2508 free base is an orally active and highly selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist with anxiolytic effects (Ki=11 nM). E-2508 free base blocks CRF-induced cAMP accumulation via CRF1 receptor inhibition. E-2508 free base is promising for research of stress-related psychiatric disorders, such as anxiety and depression [1].
    E-2508 free base
  • HY-14129
    CP 316311

    		CRFR Neurological Disease Endocrinology
    CP 316311 is a potent and selective CRF1 receptor antagonist with an IC50 value of 6.8 nM.
    CP 316311
  • HY-103379
    CP 376395 hydrochloride

    		CRFR Neurological Disease Endocrinology
    CP 376395 hydrochloride is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist [1] .
    CP 376395 hydrochloride
  • HY-103376
    NBI-27914 hydrochloride

    		CRFR Neurological Disease
    NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a Ki value of 1.7 nM [1] .
    NBI-27914 hydrochloride
  • HY-177313
    AAG561

    NVP-AAG 561

    		 CFTR Neurological Disease
    AAG561 is a corticotropin-releasing factor receptor 1 (CRF1) antagonist. AAG561 can be used for the study of the underlying emotion dysregulation of a mental disease or disorder [1].
    AAG561
  • HY-P1542
    Urotensin I

    Catostomus urotensin I

    		 CRFR Cardiovascular Disease Endocrinology
    Urotensin I (Catostomus urotensin I), a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively [1] .
    Urotensin I
  • HY-P1542B
    Urotensin I TFA

    Catostomus urotensin I TFA

    		 CRFR Cardiovascular Disease Endocrinology
    Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively [1] .
    Urotensin I TFA
  • HY-123677
    E2508

    		CRFR Neurological Disease
    E2508 is an orally active corticotropin-releasing factor 1 (CRF1) receptor antagonist with a Ki value of 11 nM for hCRF1 [1].
    E2508
  • HY-12127R
    Pexacerfont (Standard)

    BMS-562086 (Standard)

    		 CRFR Reference Standards Neurological Disease Endocrinology
    Pexacerfont (Standard) is the analytical standard of Pexacerfont. This product is intended for research and analytical applications. Pexacerfont is a selective corticotropin-releasing factor (CRF1) receptor antagonist with IC50 of 6.1±0.6 nM for human CRF1 receptor.
    Pexacerfont (Standard)
  • HY-P3785
    PKI(5-22)amide

    		PKA Neurological Disease
    PKI(5-22)amide is the active inhibitory fragment of the inhibitor of the cyclic AMP-dependent protein kinase (PKA). PKI(5-22)amide inhibits PKA activation, but fails to attenuate homologous desensitization of CRF1 receptors [1] .
    PKI(5-22)amide
  • HY-114070
    NGD 98-2

    		CRFR Neurological Disease
    NGD 98-2 is an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist
    NGD 98-2
  • HY-110310
    NGD 98-2 hydrochloride

    		CRFR Neurological Disease
    NGD 98-2 hydrochloride is an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist
    NGD 98-2 hydrochloride
  • HY-P1296A
    Urocortin, rat TFA

    Urocortin (Rattus norvegicus) TFA; Rat urocortin TFA

    		 CRFR Neurological Disease Endocrinology
    Urocortin, rat TFA (Urocortin (Rattus norvegicus) TFA) is a neuropeptide and a potent endogenous CRFR agonist with Kis of 13 nM, 1.5 nM, and 0.97 nM for human CRF1, rat CRF2α and mouse CRF2β, respectively [1] .
    Urocortin, rat TFA
  • HY-106203B
    (R)-Crinecerfont

    (R)-SSR-125543

    		 CFTR Metabolic Disease
    (R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency [1] . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (R)-Crinecerfont
  • HY-120564
    BMS-763534

    		CRFR Neurological Disease
    BMS-763534 is a CRF1 antagonist that inhibits neurological disorders such as depression and anxiety. [1].
    BMS-763534
  • HY-105332
    CRA1000

    		CRFR Neurological Disease
    CRA1000 is an orally active, selective and competitive CRF1 receptor antagonist with anxiolytic- and antidepressant-like properties [1].
    CRA1000
  • HY-12339
    NVS-CRF38

    		CRFR Endocrinology
    NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility.
    NVS-CRF38
  • HY-120148
    SM19712 free acid

    		Endothelin-Converting Enzyme (ECE) Others
    SM19712 (free acid) is an endothelin-converting enzyme-1-related compound that affects corticotropin-releasing factor receptor 1 (CRF1).
    SM19712 free acid
  • HY-110056
    NBI 35965 hydrochloride

    		CRFR Neurological Disease
    NBI 35965 hydrochloride is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a Ki value of 4 nM and a pKi value of 8.5. NBI 35965 hydrochloride does not inhibit CRF2. NBI 35965 hydrochloride reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC50 values of 7.1 and 6.9, respectively. NBI 35965 hydrochloride shows anxiolytic effects [1] .
    NBI 35965 hydrochloride
  • HY-14225
    BMS-764459

    		CRFR Cytochrome P450 Neurological Disease
    BMS-764459 is a CRF1 antagonist. BMS-764459 can be used for the research of neurological disorders such as depression and anxiety. BMS-764459 is also an atypical CYP1A1 inducer [1] .
    BMS-764459
  • HY-106203C
    Crinecerfont tosylate

    SSR-125543 tosylate

    		 CFTR Metabolic Disease
    Crinecerfont (SSR-125543) tosylate is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont tosylate blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont tosylate improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont tosylate can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency [1] . Crinecerfont tosylate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont tosylate
  • HY-107095
    JNJ19567470

    R317573; CRA5626; TAI041

    		 CRFR Neurological Disease
    JNJ19567470 (R317573) is a selective, non-peptidergic CRF type 1 receptor (CRF1) antagonist. JNJ19567470 blocks NaLac-induced panic-like behaviour and cardiovascular responses. JNJ19567470 decreases regional glucose utilization in the amygdala, and attenuates anxiety responses [1] .
    JNJ19567470
  • HY-14132
    BMS-665053

    		CRFR Neurological Disease
    BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM) [1].
    BMS-665053
  • HY-118935
    NGD9002 free base

    		Adrenergic Receptor Inflammation/Immunology
    NGD9002 free base is a new generation of selective corticotropin-releasing factor-1 (CRF-1) receptor antagonist with inhibitory activity on CRF-induced colonic function stimulation. NGD9002 free base can reduce CRF-induced fecal output response and show an inhibitory IC50 value of 4.3 mg/kg. NGD9002 free base can effectively block CRF-induced colonic secretory motility stimulation at the highest dose and reduce acute water avoidance-induced defecation. NGD9002 free base can also prevent the occurrence of pain hypersensitivity reactions to repeated colonic distension [1].
    NGD9002 free base
  • HY-106203R
    Crinecerfont (Standard)

    SSR-125543 (Standard)

    		 Reference Standards CFTR Metabolic Disease
    Crinecerfont (Standard) is the analytical standard of Crinecerfont (HY-106203). This product is intended for research and analytical applications. Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont (Standard)
  • HY-RS03170
    Crhr1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Crhr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Crhr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Crhr1 Rat Pre-designed siRNA Set A
    Crhr1 Rat Pre-designed siRNA Set A
  • HY-RS03168
    CRHR1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CRHR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CRHR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CRHR1 Human Pre-designed siRNA Set A
    CRHR1 Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: